| |
|
          |
|
|
NVENTA TO PRESENT AT BIO 2008 INTERNATIONAL
CONVENTION
FOR IMMEDIATE RELEASE - June 16, 2008
San Diego, California USA - Nventa Biopharmaceuticals
Corporation (TSX:NVN) announced today that the Company’s vice
president of corporate development, Richard Lai Fatt, Ph.D., is
scheduled to present a Company overview at the Business Forum during
the Biotechnology Industry Organization 2008 International Convention
being held in San Diego, California, June 17-20, 2008. The presentation
will take place on Wednesday, June 18, 2008, at 3:45 p.m. PDT in
Room 5B at the San Diego Convention Center.
Dr. Lai Fatt will discuss the Company’s progress with its
lead product candidate, HspE7, a novel compound intended for the
treatment of precancerous and cancerous lesions caused by the human
papillomavirus (HPV), one of the most common sexually transmitted
diseases in the world. The presentation will not be webcast.
About Nventa Biopharmaceuticals Corporation:
Nventa is developing innovative therapeutics for the treatment of
viral infections and cancer, with a focus on diseases caused by
the human papillomavirus (HPV). The Company is publicly traded on
the Toronto Stock Exchange under the symbol NVN.
For more information about Nventa Biopharmaceuticals Corporation,
please visit the Company’s website located at www.nventacorp.com.
Contact:
Donna Slade
Director, Investor Relations
9381 Judicial Drive, Suite 180
San Diego, CA USA 92121
Dir: 858.202.4945 dslade@nventacorp.com
|
Download a PDF file of this release
|
|